BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - FRA:IDP - US09062X1037 - Common Stock
144.9 EUR
+0.25 (+0.17%)
Overall IDP gets a fundamental rating of 5 out of 10. We evaluated IDP against 75 industry peers in the Biotechnology industry. IDP has an excellent financial health rating, but there are some minor concerns on its profitability. IDP has a bad growth rate and is valued cheaply. These ratings could make IDP a good candidate for value investing.
1. Profitability
1.1 Basic Checks
IDP had positive earnings in the past year.
IDP had a positive operating cash flow in the past year.
In the past 5 years IDP has always been profitable.
In the past 5 years IDP always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.51%, IDP is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
IDP's Return On Equity of 8.84% is amongst the best of the industry. IDP outperforms 81.33% of its industry peers.
IDP has a Return On Invested Capital of 9.70%. This is amongst the best in the industry. IDP outperforms 86.67% of its industry peers.
IDP had an Average Return On Invested Capital over the past 3 years of 10.57%. This is below the industry average of 12.96%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.4%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
The Profit Margin of IDP (15.99%) is better than 82.67% of its industry peers.
In the last couple of years the Profit Margin of IDP has declined.
IDP has a Operating Margin of 28.50%. This is amongst the best in the industry. IDP outperforms 85.33% of its industry peers.
IDP's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 75.24%, IDP is in the better half of the industry, outperforming 69.33% of the companies in the same industry.
IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.99% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.98%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IDP is creating some value.
IDP has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IDP has less shares outstanding
The debt/assets ratio for IDP has been reduced compared to a year ago.
2.2 Solvency
IDP has an Altman-Z score of 3.23. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.23, IDP is doing good in the industry, outperforming 78.67% of the companies in the same industry.
The Debt to FCF ratio of IDP is 2.78, which is a good value as it means it would take IDP, 2.78 years of fcf income to pay off all of its debts.
IDP has a Debt to FCF ratio of 2.78. This is amongst the best in the industry. IDP outperforms 81.33% of its industry peers.
A Debt/Equity ratio of 0.35 indicates that IDP is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.35, IDP is in line with its industry, outperforming 52.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.23 |
ROIC/WACC1.18
WACC8.25%
2.3 Liquidity
IDP has a Current Ratio of 2.72. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.72, IDP is in line with its industry, outperforming 58.67% of the companies in the same industry.
IDP has a Quick Ratio of 2.04. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
IDP's Quick ratio of 2.04 is in line compared to the rest of the industry. IDP outperforms 53.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.51% over the past year.
Measured over the past years, IDP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.31% on average per year.
IDP shows a small growth in Revenue. In the last year, the Revenue has grown by 4.77%.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
Based on estimates for the next years, IDP will show a small growth in Earnings Per Share. The EPS will grow by 0.52% on average per year.
The Revenue is expected to decrease by -0.65% on average over the next years.
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IDP is valuated reasonably with a Price/Earnings ratio of 10.03.
IDP's Price/Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 89.33% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.46, IDP is valued rather cheaply.
With a Price/Forward Earnings ratio of 10.76, the valuation of IDP can be described as very reasonable.
Based on the Price/Forward Earnings ratio, IDP is valued cheaply inside the industry as 96.00% of the companies are valued more expensively.
IDP's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.39.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.03 | ||
| Fwd PE | 10.76 |
4.2 Price Multiples
89.33% of the companies in the same industry are more expensive than IDP, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, IDP is valued cheaper than 92.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.88 | ||
| EV/EBITDA | 7.38 |
4.3 Compensation for Growth
The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
5. Dividend
5.1 Amount
No dividends for IDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IDP (11/19/2025, 7:00:00 PM)
144.9
+0.25 (+0.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap21.24B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.81
Price Target149.69 (3.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)1.04%
PT rev (3m)0.55%
EPS NQ rev (1m)-54.08%
EPS NQ rev (3m)-54.76%
EPS NY rev (1m)-4.15%
EPS NY rev (3m)1.63%
Revenue NQ rev (1m)-2.3%
Revenue NQ rev (3m)-2.13%
Revenue NY rev (1m)0.95%
Revenue NY rev (3m)5.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.03 | ||
| Fwd PE | 10.76 | ||
| P/S | 2.45 | ||
| P/FCF | 10.88 | ||
| P/OCF | 10.03 | ||
| P/B | 1.35 | ||
| P/tB | 10.32 | ||
| EV/EBITDA | 7.38 |
EPS(TTM)14.44
EY9.97%
EPS(NY)13.47
Fwd EY9.3%
FCF(TTM)13.32
FCFY9.19%
OCF(TTM)14.44
OCFY9.97%
SpS59.24
BVpS107.16
TBVpS14.04
PEG (NY)N/A
PEG (5Y)N/A
Graham Number186.59
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.99% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.4%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.16%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.98%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.56% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.23 |
F-Score5
WACC8.25%
ROIC/WACC1.18
Cap/Depr(3y)54.41%
Cap/Depr(5y)68.88%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.36%
Profit Quality(5y)121%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y1.64%
FCF growth 1Y120.54%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.48%
OCF growth 3Y-7.55%
OCF growth 5Y-16.48%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
Can you provide the valuation status for BIOGEN INC?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for IDP stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
Can you provide the expected EPS growth for IDP stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -5.79% in the next year.